Cargando…

Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease

The autosomal dominant form of Alzheimer’s disease (ADAD) is far less prevalent than late onset Alzheimer’s disease (LOAD), but enables well-informed prospective studies, since symptom onset is near certain and age of onset is predictable. Our aim was to discover plasma proteins associated with earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Muenchhoff, Julia, Poljak, Anne, Thalamuthu, Anbupalam, Gupta, Veer B., Chatterjee, Pratishtha, Raftery, Mark, Masters, Colin L., Morris, John C., Bateman, Randall J., Fagan, Anne M., Martins, Ralph N., Sachdev, Perminder S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933916/
https://www.ncbi.nlm.nih.gov/pubmed/27381087
http://dx.doi.org/10.1038/srep29078
_version_ 1782441248450150400
author Muenchhoff, Julia
Poljak, Anne
Thalamuthu, Anbupalam
Gupta, Veer B.
Chatterjee, Pratishtha
Raftery, Mark
Masters, Colin L.
Morris, John C.
Bateman, Randall J.
Fagan, Anne M.
Martins, Ralph N.
Sachdev, Perminder S.
author_facet Muenchhoff, Julia
Poljak, Anne
Thalamuthu, Anbupalam
Gupta, Veer B.
Chatterjee, Pratishtha
Raftery, Mark
Masters, Colin L.
Morris, John C.
Bateman, Randall J.
Fagan, Anne M.
Martins, Ralph N.
Sachdev, Perminder S.
author_sort Muenchhoff, Julia
collection PubMed
description The autosomal dominant form of Alzheimer’s disease (ADAD) is far less prevalent than late onset Alzheimer’s disease (LOAD), but enables well-informed prospective studies, since symptom onset is near certain and age of onset is predictable. Our aim was to discover plasma proteins associated with early AD pathology by investigating plasma protein changes at the asymptomatic and symptomatic stages of ADAD. Eighty-one proteins were compared across asymptomatic mutation carriers (aMC, n = 15), symptomatic mutation carriers (sMC, n = 8) and related noncarriers (NC, n = 12). Proteins were also tested for associations with cognitive measures, brain amyloid deposition and glucose metabolism. Fewer changes were observed at the asymptomatic than symptomatic stage with seven and 16 proteins altered significantly in aMC and sMC, respectively. This included complement components C3, C5, C6, apolipoproteins A-I, A-IV, C-I and M, histidine-rich glycoprotein, heparin cofactor II and attractin, which are involved in inflammation, lipid metabolism and vascular health. Proteins involved in lipid metabolism differed only at the symptomatic stage, whereas changes in inflammation and vascular health were evident at asymptomatic and symptomatic stages. Due to increasing evidence supporting the usefulness of ADAD as a model for LOAD, these proteins warrant further investigation into their potential association with early stages of LOAD.
format Online
Article
Text
id pubmed-4933916
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-49339162016-07-08 Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease Muenchhoff, Julia Poljak, Anne Thalamuthu, Anbupalam Gupta, Veer B. Chatterjee, Pratishtha Raftery, Mark Masters, Colin L. Morris, John C. Bateman, Randall J. Fagan, Anne M. Martins, Ralph N. Sachdev, Perminder S. Sci Rep Article The autosomal dominant form of Alzheimer’s disease (ADAD) is far less prevalent than late onset Alzheimer’s disease (LOAD), but enables well-informed prospective studies, since symptom onset is near certain and age of onset is predictable. Our aim was to discover plasma proteins associated with early AD pathology by investigating plasma protein changes at the asymptomatic and symptomatic stages of ADAD. Eighty-one proteins were compared across asymptomatic mutation carriers (aMC, n = 15), symptomatic mutation carriers (sMC, n = 8) and related noncarriers (NC, n = 12). Proteins were also tested for associations with cognitive measures, brain amyloid deposition and glucose metabolism. Fewer changes were observed at the asymptomatic than symptomatic stage with seven and 16 proteins altered significantly in aMC and sMC, respectively. This included complement components C3, C5, C6, apolipoproteins A-I, A-IV, C-I and M, histidine-rich glycoprotein, heparin cofactor II and attractin, which are involved in inflammation, lipid metabolism and vascular health. Proteins involved in lipid metabolism differed only at the symptomatic stage, whereas changes in inflammation and vascular health were evident at asymptomatic and symptomatic stages. Due to increasing evidence supporting the usefulness of ADAD as a model for LOAD, these proteins warrant further investigation into their potential association with early stages of LOAD. Nature Publishing Group 2016-07-06 /pmc/articles/PMC4933916/ /pubmed/27381087 http://dx.doi.org/10.1038/srep29078 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Muenchhoff, Julia
Poljak, Anne
Thalamuthu, Anbupalam
Gupta, Veer B.
Chatterjee, Pratishtha
Raftery, Mark
Masters, Colin L.
Morris, John C.
Bateman, Randall J.
Fagan, Anne M.
Martins, Ralph N.
Sachdev, Perminder S.
Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease
title Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease
title_full Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease
title_fullStr Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease
title_full_unstemmed Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease
title_short Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease
title_sort changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933916/
https://www.ncbi.nlm.nih.gov/pubmed/27381087
http://dx.doi.org/10.1038/srep29078
work_keys_str_mv AT muenchhoffjulia changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT poljakanne changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT thalamuthuanbupalam changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT guptaveerb changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT chatterjeepratishtha changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT rafterymark changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT masterscolinl changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT morrisjohnc changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT batemanrandallj changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT faganannem changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT martinsralphn changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease
AT sachdevperminders changesintheplasmaproteomeatasymptomaticandsymptomaticstagesofautosomaldominantalzheimersdisease